Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer Sees Deeper Price Cuts, Lilly Maintains China Momentum – Emerging Market Earnings Roundup (Part 2)

Feb 07 2012

• By Brian Yang

Related Content

Post-Lipitor Pfizer Will Have Two Business Models: Innovation And Value

Jan 31 2012

With Pfizer As Cornerstone Investor, Will Shanghai Pharmaceutical Be Largest Pharma IPO Ever?

May 10 2011

Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)

Mar 07 2011

Big Pharma Takes Another Haircut As China Slashes Drug Prices In Two Largest Therapy Fields

Mar 08 2011

Eli Lilly & Co. Global External R&D-Asia VP Tony Zhang on Lilly's FIPNET Strategies In China: An Interview With PharmAsia News

Jan 12 2011

Pfizer's Salomon Azoulay And Bing Yan On Prevenar, Partnering In China Post-Lipitor: An Interview With PharmAsia News (Part 2 of 2)

Aug 17 2011

Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun

Jun 02 2011

Are Emerging Markets Part Of Big Pharma's Core Business?

Jun 09 2011

Related Companies

Novartis AG

Abbott

Pfizer Inc.

Eli Lilly and Company

Shanghai Pharmaceutical Group Co., Ltd

Zhejiang Hisun Pharmaceutical Co. Ltd.

Additional Topics

Asia Pacific BioPharmaceutical

More from Focus On Asia

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window